Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI.

Thyroid. 2014 Oct;24(10):1508-14. doi: 10.1089/thy.2014.0125. Epub 2014 Aug 27.

2.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP.

Ann Oncol. 2014 Aug;25(8):1603-8. doi: 10.1093/annonc/mdu184. Epub 2014 May 14.

3.

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.

J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95. doi: 10.1210/jc.2009-1923. Epub 2010 Apr 14.

PMID:
20392874
4.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.

5.

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH.

J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5.

6.

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

Krajewska J, Olczyk T, Jarzab B.

Expert Rev Clin Pharmacol. 2016;9(1):69-79. doi: 10.1586/17512433.2016.1102052. Epub 2015 Nov 4. Review.

PMID:
26536165
7.

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M.

J Clin Oncol. 2010 Feb 10;28(5):767-72. doi: 10.1200/JCO.2009.23.6604. Epub 2010 Jan 11.

8.

Lenvatinib: Role in thyroid cancer and other solid tumors.

Cabanillas ME, Habra MA.

Cancer Treat Rev. 2016 Jan;42:47-55. doi: 10.1016/j.ctrv.2015.11.003. Epub 2015 Dec 2. Review.

9.

Cabozantinib: a review of its use in patients with medullary thyroid cancer.

Hoy SM.

Drugs. 2014 Aug;74(12):1435-44. doi: 10.1007/s40265-014-0265-x. Review.

PMID:
25056653
10.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R.

J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.

11.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.

J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.

12.

Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.

Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E.

Eur J Endocrinol. 2012 Nov;167(5):643-50. doi: 10.1530/EJE-12-0405. Epub 2012 Aug 23.

13.

Cabozantinib for the treatment of advanced medullary thyroid cancer.

Nagilla M, Brown RL, Cohen EE.

Adv Ther. 2012 Nov;29(11):925-34. doi: 10.1007/s12325-012-0060-6. Epub 2012 Oct 25. Review.

PMID:
23104465
14.

Cabozantinib in Thyroid Cancer.

Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenga S, Miccoli P, Antonelli A.

Recent Pat Anticancer Drug Discov. 2015;10(3):259-69. Review.

PMID:
26152149
15.

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer.

Viola D, Cappagli V, Elisei R.

Future Oncol. 2013 Aug;9(8):1083-92. doi: 10.2217/fon.13.128.

PMID:
23902240
16.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators.

N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

PMID:
26406150
17.

Cabozantinib approved for advanced medullary thyroid cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Jan 15;70(2):88. doi: 10.2146/news130005. No abstract available.

PMID:
23292257
18.

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R.

J Clin Endocrinol Metab. 2011 Apr;96(4):997-1005. doi: 10.1210/jc.2010-1899. Epub 2011 Feb 2. Erratum in: J Clin Endocrinol Metab. 2012 Apr;97(4):1399. J Clin Endocrinol Metab. 2011 Jul;96(7):2286. Busaidy, Naifa L [added]; El Naggar, Alder K [corrected to El Naggar, Adel K].

19.

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.

Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW.

Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24.

20.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

Items per page

Supplemental Content

Write to the Help Desk